IMUGENE LIMITED — Board/Management Information 2016

Apr 11, 2016

==> picture [167 x 75] intentionally omitted <==

Imugene appoints Dr. Yelena Janjigian as a Scientific Advisory Board member

Melbourne, Australia, 12 April 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that Dr Yelena Janjigian of Memorial Sloan Kettering Cancer Center in New York has joined the company’s Scientific Advisory Board. Dr. Janjigian holds board certifications for internal medicine and medical oncology from New York University of Medicine.

Dr Janjigian is a medical oncologist who specializes in the treatment of malignancies of the gastrointestinal tract, including oesophageal and gastric cancer. Her research focuses on the development of new treatments for patients with these kinds of cancers. Dr Janjigian has run clinical and translational studies designed to develop a better prevention, early diagnosis, staging, and treatment strategies and has been Principal Investigator on a number of clinical trials conducted at Memorial Sloan-Kettering.

Imugene’s Scientific Advisory Board now comprises Dr Janjigian plus Professors Christoph Zielinski and Ursula Wiedermann of the Medical University of Vienna, who did the initial development of the science behind Imugene’s B Cell peptide vaccines, and Dr Neil Segal, also an oncologist at Memorial Sloan-Kettering.

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx’s successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies.

For further information, please visit www.imugene.com. Sign up to follow @TeamImugene on Twitter at http://www.twitter.com/TeamImugene. To follow Imugene on Facebook visit www.facebook.com/imugene.

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), leslie.chong[at]imugene.com

Stuart Roberts, Head of Corporate Development Tel: +61 447 247 909, sroberts[at]imugene.com

Paul Hopper, Executive Chairman Tel: +61 406 671 515 (Australia), receptogen[at]earthlink.net

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com